BMY•benzinga•
Bristol Myers Squibb Presents Updated Clinical Findings On CELMoD Agents Mezigdomide And Iberdomide In Multiple Myeloma, Golcadomide In Non-Hodgkin Lymphoma, And First Results Evaluating Oral BCL6 LDD In Non-Hodgkin Lymphoma, At EHA 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 12, 2025 by benzinga